

ULSS 13


Divisione oculistica Dolo-Mirano

Direttore Dr. Romeo Altafini

Retinopatie e Maculopatie



Dott.ssa Giorgia Sanguinetti

16 Ottobre 2016




La retina

Sottilissima membrana che riveste internamente l'occhio
Costituita di cellule nervose






EP - epitelio pigmentato
B - cellule bipolari
O - cellule orizzontali
M - cellule di Muller

C - fotorecettori(coni)
S - fotorecettori(bastoncelli)
A - cellule amacrine
G - cellule ganglionari




La macula

Deputata alla percezione delle immagini




La retina

- La luce visibile:
porzione dello spettro
elettromagnetico visibile
dall'occhio umano,
approssimativamente
compresa tra 400 e 700
nanometri di lunghezza
d'onda




La retina




angelo kathy, 2010

La retina




La retina


- Stazioni neurofunzionali:
 - fotorecettori (coni e bastoncelli)
 - cellule bipolari
 - cellule ganglionari



CONI e BASTONCELLI




Copyright © 2008 Pearson Education, Inc., publishing as Benjamin Cummings






Copyright © 2008 Pearson Education, Inc., publishing as Benjamin Cummings

CONI e BASTONCELLI






Phototransduction


- Photons hit the pigment of a photoreceptor → → → enzymes are activated in the cell which modify its state of polarization





Photoreception - In More Detail




Photoreception




Bleaching and Regeneration of Visual Pigments




Convergence and Ganglion Cell Function



Il nervo ottico




(b)



Macula lutea Fovea Optic disc (blind spot) Central retinal artery and vein emerging from center of optic disc


(c)

The Visual Pathways



Cecità e ipovisione

CECITA' E IPOVISIONE
www.cprnonvedenti.it



CIECHI TOTALI: AV \leq MOTU MANUS
CAMPO VISIVO $<$ 3%

CIECHI PARZIALI: AV \leq 1/20
CAMPO VISIVO $<$ 10%

IPOVEDENTI GRAVI: AV \leq 1/10
CAMPO VISIVO $<$ 30%


IPOVEDENTI MEDIO-GRAVI: AV \leq 2/10
CAMPO VISIVO $<$ 50%

IPOVEDENTI LIEVI: AV \leq 3/10
CAMPO VISIVO $<$ 60%


Cause di cecità per gruppi etnici

AV $\leq 1/20$


Razza bianca



Razza nera



- DMLE
- Cataratta
- Glaucoma
- RD
- altro




Razza ispanica

Cause di cecità

AV \leq 1/20

Nei paesi industrializzati
la **retinopatia diabetica**
è la **prima causa di cecità**
in età lavorativa

Degenerazione maculare legata all'età (DMLE)



- La **Degenerazione Maculare Legata all'Età** (DMLE o AMD) è una patologia cronica che colpisce la porzione più importante della retina (*macula*), sede della visione distinta ⁽¹⁾



Incidenza DMLE

- DMLE iniziale: 1.3% – 2.2% x anno
- DMLE evoluta: 0.01% – 1% x anno

Hisayama study 2005

Copenhagen City Eye Study 2005


Visual Impairment Project 2004

Barbados Eye Study 2004

Blue Mountains Eye Study 2003

Beaver Dam Eye study 2002

Prevalenza DMLE



AMD: prevalenza (in almeno 1 occhio) come % della popolazione per fascia d'età



Degenerazione maculare legata all'età (DMLE)

STUDIO MORFO-FUNZIONALE



-OFTALMOSCOPIA



Degenerazione maculare legata all'età (DMLE)




Degenerazione maculare legata all'età (DMLE)



FOTORECETTORI →


EPITELIO PIGMENTATO RETINICO →

COROIDE →



Degenerazione maculare legata all'età (DMLE)


DRUSEN



FOTORECETTORI →

EPITELIO PIGMENTATO RETINICO →

COROIDE →



Degenerazione maculare legata all'età (DMLE)


ATROFIA



FOTORECETTORI →




EPITELIO PIGMENTATO RETINICO →

COROIDE →



Degenerazione maculare legata all'età (DMLE)

NEOVASCULARIZZAZIONE
COROIDEALE
(CNV)



Degenerazione maculare legata all'età (DMLE)


**DMLE EVOLUTA:
CICATRICE
FIBROVASCOLARE**




FOTORECETTORI →

EPITELIO PIGMENTATO RETINICO →

COROIDE →



Degenerazione maculare legata all'età (DMLE)




Degenerazione maculare legata all'età (DMLE)

STUDIO MORFO-FUNZIONALE


-AUTOFLUORESCENZA



-FLUORANGIOGRAFIA



- ANGIOGRAFIA AL VERDE INDOCIANINA







Degenerazione maculare legata all'età (DMLE)

STUDIO MORFO-FUNZIONALE

-FLUORANGIOGRAFIA

DRUSEN



Degenerazione maculare legata all'età (DMLE)







Degenerazione maculare legata all'età (DMLE)

STUDIO MORFO-FUNZIONALE


-FLUORANGIOGRAFIA

ATROFIA / PIGMENTO






Degenerazione maculare legata all'età (DMLE)



Degenerazione maculare legata all'età (DMLE)

FLUORANGIOGRAFIA

NEOVASCULARIZZAZIONE COROIDEALE





Degenerazione maculare legata all'età (DMLE)

STUDIO MORFO-FUNZIONALE

- OCT

- MICROPERIMETRIA



DIAGNOSTICA “DI SUPERFICIE”

Oftalmoscopia

Fluorangiografia

DIAGNOSTICA “DI SPESSORE”


Ecografia:

Risoluzione: 150 μ

OCT:


Risoluzione: 7 - 15 μ



OCT



TOMOGRAFIA A COERENZA OTTICA



PRINCIPI DI FUNZIONAMENTO DELL'OCT









Focus: 1.08 D

Scan angle: 29.2°




Partial coherent light is projected into the retina
 The light scatter and reflects back from different
 layers of the vitreo-retina, retina and choroid







Averaging 20 of 20




OCT has become progressively more focused since its introduction into clinical ophthalmology



1996




2001





2008

Currently commercial OCTs map the macular anatomy to a level of detail approaching *in vivo* optical biopsy





HR Spectral OCT/SLO





Outer Retinal Layers



REFLETTIVITA' DI STRUTTURE FISIOLOGICHE

ALTA:


Strato delle fibre nervose, membrana limitante esterna, giunzione SE/SI fotorecettori, EPR-coriocapillare

MEDIA:

Strati plessiformi interno ed esterno

BASSA:

Strati nucleari interno ed esterno, fotorecettori











**REFLETTIVITA' DI
STRUTTURE
PATOLOGICHE**



DRUSEN



ATROFIA CORIORETINICA





RIDUZIONE DI SPESSORE DI RETINA, EPR E CORIOCAPILLARE =

MINORE ATTENUAZIONE =






MAGGIORE ESPOSIZIONE COROIDEALE =

IPERREFLETTIVITA' + BACKSCATTERING

Neovascolarizzazione coroideale nella DMLE






ESSUDATI DURI



STRUTTURE INTRARETINICHE DENSE =

**IPERREFLETTIVITA' INTRARETINICA -
EVENTUALE CONO D'OMBRA**

LIQUIDO INTRARETINICO




**FLUIDO INTRARETINICO
IPO-ARIFLETENTE =**



SPAZI VUOTI INTRARETINICI

**CONSERVAZIONE DELLE CELLULE DI
MULLER (EDEMA CISTOIDE) =**

SEPIMENTAZIONE DEGLI SPAZI






LIQUIDO SOTTONEURORETINICO



FLUIDO IPO-ARIFLETTENTE **SOPRA** LA BANDA IPERRIFLETTENTE =
DISTACCO NEUROEPITELIALE

FLUIDO IPO-ARIFLETTENTE **SOTTO** LA BANDA IPERRIFLETTENTE =
DISTACCO DELL'EPR (tendenzialmente cupoliforme)

EMORRAGIA



EMOGLOBINA - ELEVATA DENSITA' =

IPERREFLETTIVITA' CON CONO D'OMBRA



Degenerazione maculare legata all'età (DMLE)

Raccolta attenta dei segni e sintomi riferiti dal paziente:

- Riduzione visiva

- Metamorfopsie

- Scotoma campo visivo centrale




Degenerazione maculare legata all'età (DMLE)


Scotoma campo visivo centrale



*Visione normale di un testo:
solo la regione maculare
riconosce i dettagli più piccoli*



*La cicatrice maculare dovuta
alla neovascolarizzazione
corideale causa una macchia o
scotoma centrale e distorsione
dell'immagine.*



EZIOPATOGENESI

Fattori
genetici

Fattori
ambientali


Invecchiamento

Radicali liberi

Alterato metabolismo
fotorecettori e EPR

Fattori flogogeni

Formazione delle drusen



CNV

Alterato equilibrio fattori
angiogenici

-
- **Ereditarietà DMLE: 46%**
 - **Ereditarietà DMLE evoluta: 71%**

Seddon, 2005

Fumo di sigaretta

- Aumenta fino a 2.4 volte il rischio (fumatori > 25 sigarette/die)
- Stress ossidativo
- Riduce pigmento maculare
- Danno microcircolo

Hisayama Study 2005

AREDS report n.19 2005

Blue Mountains Eye Study 2002

AREDS report n. 3 2000

Physicians' Health Study 1996

Nurses' Health Study 1995-1996

Fattori nutrizionali

- Elevato introito di grassi aumenta fino a 2.9 volte il rischio di progressione DMLE
- Pesce e frutta secca riducono rischio
- Obesità associata a progressione DMLE
- Stress ossidativo
- Infiammazione
- Ruolo antiossidanti

AREDS report n.19 2005


Seddon 2003

AREDS report n. 3 2000

La Retinopatia Diabetica

Nel nostro paese la retinopatia diabetica rappresenta la principale complicanza oculare del diabete mellito, e la maggiore causa di cecità nella popolazione in età lavorativa

Stima di crescita (nel mondo) dei diabetici entro il 2025




Il diabete è causa di gravi complicanze invalidanti che coinvolgono principalmente occhio, rene, sistema nervoso periferico e sistema cardio-circolatorio

(Microangiopatia e Macroangiopatia)

Microangiopatia

Macroangiopatia






Lesioni dei capillari

Capillare normale

Capillare alterato

Capillare normale







Capillare patologico


Occlusione capillare

Microaneurismi

Evoluzione dei microaneurismi




Capillare alterato



Capillare patologico

Sfiancamento delle pareti del capillare con formazione di microaneurismi


Alterazioni delle connessioni fra le cellule endoteliali con danni della barriera emato-retinica



Membrana basale ispessita

Nuclei alterati

Occlusione capillare



Retinopatia diabetica


Alterazione dell'autoregolazione del flusso sanguigno
(presente nei soggetti con DM anche senza RD)
per perdita della funzionalità dei periciti.



Retinopatia diabetica

non proliferante

microaneurismi




Retinopatia diabetica

non proliferante

microaneurismi

microemorragie



Retinopatia diabetica


non proliferante

microaneurismi

microemorragie

essudati duri

IRMA



Retinopatia diabetica

non proliferante


microaneurismi

microemorragie

essudati duri

IRMA


noduli cotonosi



Retinopatia diabetica

non proliferante


maculopatia
edematosa



Retinopatia diabetica

non proliferante

maculopatia
ischemica




Retinopatia diabetica

non proliferante

i piccoli vasellini della retina diventano deboli, fragili, permeabili e tendono ad occludersi

quando si occludono creano aree ischemiche cioè poco irrorate dal sangue e dall'ossigeno

la retina quindi per mantenere la circolazione crea dei nuovi vasi passando al quadro di:





Retinopatia diabetica

proliferante

neovasi

I neovasi si formano spesso in prossimità delle aree di ischemia, ma possono anche comparire a distanza (papilla, iride, angolo irido-corneale).
Si ipotizza che a livello delle aree di ischemia si formi un fattore neovascolare che stimola la formazione di neovasi




Retinopatia diabetica

proliferante

i neo-vasi sono fragili e tendono a sanguinare (emovitreo)

possono “tirare” il tessuto retinico creando un distacco di retina

possono causare un glaucoma neovascolare



International Clinical Diabetic Retinopathy Disease Severity Scale

Proposed Disease Severity Level	Findings Observable upon Dilated Ophthalmoscopy
No apparent retinopathy	No abnormalities
Mild nonproliferative diabetic retinopathy	Microaneurysms only
Moderate nonproliferative diabetic retinopathy	More than just microaneurysms but less than severe NPDR
Severe nonproliferative diabetic retinopathy	Any of the following: More than 20 intraretinal hemorrhages in each of four quadrants Definite venous beading in two or more quadrants Prominent IRMA in one or more quadrants and no signs of proliferative retinopathy.
Proliferative diabetic retinopathy	One or both of the following: Neovascularization Vitreous/preretinal hemorrhage

[Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales](#)

Classificazione della retinopatia diabetica (RD)

- Assenza di RD
 - RD non proliferante
 - Lieve
 - Moderata
 - Avanzata (o grave o pre-proliferante)
 - RD proliferante
 - Oftalmopatia diabetica avanzata
 - Rubeosi dell'iride
 - Glaucoma neovascolare
 - Proliferazione neovasi nel vitreo
- Maculopatia**
- Edema maculare non clinicamente significativo
 - Edema maculare clinicamente significativo
 - Maculopatia ischemica

Diagnostica della retinopatia diabetica

Una volta individuati i pazienti che necessitano di approfondimento diagnostico oftalmologico (mediante uno screening mirato), si rende necessaria l'esecuzione di una visita oculistica completa e, qualora si vogliano documentare le lesioni iniziali che caratterizzano la retinopatia, è indicata l'esecuzione di fotografie a colori o in bianco e nero del fondo oculare (retinografia)






Schema di fondo oculare normale (valori numerici in micron)

Area papillare

1. Area discale
2. Area iuxtapapillare
3. Area parapapillare
4. Area peripapillare



Area maculare

1. Foveola
2. Fovea
3. Parafovea
4. Perifovea


Fondo sano



Retinopatia diabetica lieve




Microaneurismi






Retinopatia diabetica con maculopatia essudativa



Retinopatia diabetica proliferante




Retinografia di retinopatia diabetica proliferante



Adattato da: "Retinopatia Diabetica"
Del Prof. B. Lumbroso



Fluorangiografia (FAG)



Si inietta del colorante (fluoresceina) in vena e poi si scattano delle foto al fondo dell'occhio in modo da vedere alterazioni morfologiche e funzionali dei vasi retinici.

In particolare si vede se il liquido trasuda dai vasi e se ci sono delle aree non perfuse.

Apparecchiatura per angiografia a fluorescenza computerizzata





Gli scopi della fluorangiografia retinica sono i seguenti:

- a) Interpretazione patogenetica dell'edema maculare
- b) Individuazione di neovascolarizzazioni dubbie
- c) Esatta definizione delle zone retiniche ischemiche
- d) Studio della macula nei casi di perdita visiva non giustificata clinicamente


La fluorangiografia retinica non è indicata per lo screening e la diagnosi della retinopatia diabetica.

Fluorangiografia di un fondo sano





Fluorangiografia
di retinopatia
diabetica lieve
non proliferante




Fluorangiografia di retinopatia diabetica non proliferante con microaneurismi




Fluorangiografia di retinopatia diabetica non proliferante con IRMA

(Alterazioni Microvascolari IntraRetiniche)




Fluorangiografia di retinopatia diabetica con



Alterazioni del calibro delle vene
(dilatazione, aspetto moniliforme, formazione di anse)
adiacenti ad aree di non perfusione



Fluorangiografia di retinopatia diabetica ischemica e trombosi venosa



Retinopatia diabetica proliferante (fluorangiografia)





Adattato da: "Retinopatia Diabetica"
Del Prof. B. Lumbroso

(In verde diffusione
di fluoresceina)

Fluorangiografia di retinopatia diabetica proliferante





Fluorangiografia di retinopatia diabetica proliferante parzialmente trattata



Fluorangiografia di retinopatia diabetica proliferante

I neovasi si propagano sulla superficie della retina e lungo i tralci vitreali, sono molto fragili e possono esitare in emorragie vitreali



In particolari situazioni cliniche, o per acquisire dati utili a fini prognostici e/o terapeutici, ci si può avvalere dei seguenti ulteriori esami:

- ecografia oculare
- iridografia
- tomografia ottica a luce coerente (OCT)



Ecografo A e B scan




L'ecografia oculare trova indicazione nei casi in cui la visualizzazione del fondo oculare sia resa difficile da opacità dei mezzi diottrici (cataratta, emorragia endovitrea) o per meglio definire i rapporti anatomici tra corpo vitreo e retina.

Ecografia B scan e A scan normale




Tracciato ecografico del bulbo oculare ottenuto con la tecnica B scan a contatto in proiezione assiale verticale, che mette in evidenza il cristallino ed una zona acusticamente silente corrispondente al corpo vitreo, delimitato dalla parete del bulbo oculare.

Tracciato ecografico del bulbo oculare ottenuto con la tecnica A scan standardizzata, in cui si evidenzia una zona acusticamente vuota seguita da un picco ad alta riflettività a risalita rapida, corrispondente all'interfaccia vitreo retinica, seguita dai picchi provenienti dalle strutture orbitarie.




Ecografia B scan e A scan in diabetico con emovitreo



Tracciato ecografico del bulbo oculare ottenuto con tecnica B-scan a contatto. Presenza di emovitreo con enhancement della corticale vitreale e di una zona di silenzio acustico tra quest'ultima e la superficie retinica, corrispondente allo spazio retroialoideo apparentemente normale.

Tracciato ecografico del bulbo oculare ottenuto con tecnica A-scan a contatto. Presenza di emovitreo e una zona che mette meglio in evidenza dei picchi a bassa riflettività nello spazio retroialoideo, indice di un intorbidamento emorragico anche di quest'ultimo.



Ecografia normale

B scan




Ecografia diabetico con emovitreo


B scan



A scan





A scan




- ecografia oculare
- iridografia
- tomografia ottica a luce coerente (OCT)

L'iridografia può essere utile per una precoce diagnosi di neovascolarizzazione dell'iride e per avere informazioni indirette sulla microangiopatia retinica se non accessibile ad un esame diretto.


Fluorangiografia Iridea



Fluorangiografia Iridea




FAG iride normale




FAG iride retinopatia
diabetica

(Rubeosis Iridea)


Fluorangiografia dell' edema maculare cistoide in via di strutturazione




Fluorangiografia dell' edema maculare cistoide strutturato



Fluorangiografia di grave edema cistoide maculare con pseudoforo



Diabetic Macular Edema Prevalence





INTERNATIONAL CLINICAL DIABETIC MACULAR EDEMA
DISEASE SEVERITY SCALE


2 major levels, with subcategories for diabetic macular edema

Proposed Disease Severity Level	Findings Observable Upon Dilated Ophthalmoscopy
Diabetic Macular Edema Absent	No retinal thickening or hard exudates in posterior pole
Diabetic Macular Edema Present	Some retinal thickening or hard exudates in posterior pole

If diabetic macular edema is present, it can be categorized as follows:

Proposed Disease Severity Level	Findings Observable Upon Dilated Ophthalmoscopy *
Diabetic Macular Edema Present	<input type="checkbox"/> Mild Diabetic Macular Edema Some retinal thickening or hard exudates in posterior pole but distant from the center of the macula
	<input type="checkbox"/> Moderate Diabetic Macular Edema Retinal thickening or hard exudates approaching the center of the macula but not involving the center
	<input type="checkbox"/> Severe Diabetic Macular Edema Retinal thickening or hard exudates involving the center of the macula

* Hard exudates are a sign of current or previous macular edema. Diabetic macular edema is defined as retinal thickening and this requires a 3-dimensional assessment that is best performed by a dilated examination using slit-lamp biomicroscopy and/or stereo fundus photography. A more detailed table for the International Clinical DME Disease Severity Scale is available, with more explanation of the disease severity levels, definition of CSME, and management options. Please contact Flora Lum, M.D. at the AAO, 415 561-8500.



Diabetic Macular
Edema Absent

No retinal thickening or hard exudates in posterior pole


Diabetic Macular
Edema Present

Some retinal thickening or hard exudates in posterior pole




Mild Diabetic Macular Edema

Some retinal thickening or hard exudates in posterior pole but distant from the center of the macula



Moderate Diabetic Macular Edema

Retinal thickening or hard exudates approaching the center of the macula but not involving the center



Severe Diabetic Macular Edema

Retinal thickening or hard exudates involving the center of the macula









International Clinical Diabetic Macular Edema Disease Severity Scale

Proposed disease severity level	Findings observable upon dilated ophthalmoscopy
DME apparently absent	No apparent retinal thickening or hard exudates in posterior pole
DME apparently present	Some apparent retinal thickening or hard exudates in posterior pole
DME present	Mild DME (some retinal thickening or hard exudates in posterior pole but distant from the center of the macula) Moderate DME (retinal thickening or hard exudates approaching the center of the macula but not involving the center) Severe DME (retinal thickening or hard exudates involving the center of the macula)

Proposed International Clinical Diabetic
Retinopathy and Diabetic Macular Edema
Disease Severity Scales



Ophthalmology Volume 110, Number 9, September 2003







Maculopatia ischemica

OCCLUSIONE CAPILLARE





ALLARGAMENTO DELLA ZONA AVASCOLARE FOVEALE

(se >1000 micron l'acuità visiva è fortemente compromessa)

- ecografia oculare
- iridografia
- tomografia ottica a luce coerente (OCT)


Tomografia ottica a luce coerente (OCT)

OCT al fine di quantificare e documentare lo spessore retinico a livello maculare e per meglio visualizzare le eventuali trazioni vitreo-retiniche.



L' OCT (Optical Coherence Tomography)




L' OCT (Optical Coherence Tomography) è una moderna tecnica diagnostica per immagini basata sull'analisi della riflessione di una radiazione semicoerente da parte del tessuto esaminato.





Fondo sano



Sezione OCT normale






Emorragie retiniche







Adattato da: "Retinopatia Diabetica"
Del Prof. B. Lumbroso


Essudati duri




Edema maculare cistoide ed essudati



Edema maculare diffuso non cistoide








Edema maculare cistoide


OCT

Mappa degli spessori retinici




Forme di Edema Maculare


spugnoso (42% dei casi)




cistoide (12% dei casi)




spugnoso, distacco sieroso e cistoide (5% dei casi)



spugnoso e distacco sieroso (10% dei casi)



spugnoso e cistoide (30% dei casi)




Otani, Kishi and Maruyama
Am J Ophthalmol 1999; 127:688-633

**Cenni sulla prevenzione
della
Retinopatia diabetica**

La durata della malattia è il maggiore fattore di rischio per l'evoluzione della retinopatia diabetica.

✓ Dopo 5 anni	20%
✓ Dopo 10 anni	45 – 55%
✓ Dopo 15 anni	80%

Prevalence of diabetic retinopathy after 20 years of diagnosis



I principali fattori di rischio associati alla comparsa più precoce e ad una evoluzione più rapida della retinopatia sono:

- la durata del diabete
- lo scompenso glicemico
- l'eventuale ipertensione sistemica concomitante

Fattori di rischio



NON MODIFICABILI

- ✓ età di insorgenza
- ✓ durata della malattia
- ✓ genetica



MODIFICABILI

- ✓ iperglicemia
- ✓ ipertensione arteriosa
- ✓ microalbuminuria
- ✓ colesterolo - trigliceridi
- ✓ nefropatia
- ✓ gravidanza
- ✓ fumo

Sulla prevenzione della retinopatia diabetica

**E' indispensabile stretto controllo
dell'iperglicemia e dell'ipertensione
per ridurre la comparsa e/o l'evoluzione
della retinopatia diabetica**

**La dislipidemia
rappresenta un fattore di rischio per la perdita del visus**

**La gravidanza
è un fattore di rischio per la progressione della retinopatia**

**Il fumo
è un fattore di rischio per malattie
cardiovascolari in tutti i pazienti con diabete**



**The Effect of Intensive Diabetes Treatment
On the Progression of Diabetic Retinopathy
In Insulin-Dependent Diabetes Mellitus**

The Diabetes Control and Complications Trial

The Diabetes Control and Complications Trial Research Group

Intensive control reduced the risk of developing retinopathy by 76% and slowed progression of retinopathy by 54%; intensive control also reduced the risk of clinical neuropathy by 60% and albuminuria by 54%.

Primary prevention

Strict glycemc control

Blood pressure control

Secondary prevention

Screening RD

Tertiary prevention




Retinal Laser photocoagulation

Vitrectomy


Sintomatologia

Le alterazioni della vista sono sempre tardive rispetto all'insorgere della malattia che può evolvere a lungo asintomatica

La diminuzione della vista si ha solo quando la malattia coinvolge la regione centrale della retina (macula)



Prevenzione



Prima visita oculistica in dilatazione:

Diabete tipo I : alla diagnosi, dopo 5 anni dalla diagnosi o alla pubertà

Diabete tipo II : alla diagnosi

Gravidanza : alla conferma della gravidanza, ogni tre mesi fino al parto

RECOMMENDED EYE EXAMINATION SCHEDULE

Diabetes Type	Recommended Time of First Examination	Recommended Follow-up*
Type 1	3-5 years after diagnosis	Yearly
Type 2	At time of diagnosis	Yearly
Prior to pregnancy (type 1 or type 2)	Prior to conception and early in the first trimester	No retinopathy to mild moderate NPDR every 3-12 months Severe NPDR or worse every 1-3 months.

*Abnormal findings may dictate more frequent follow-up examinations

Primary prevention

Strict glycemic control

Blood pressure control

Secondary prevention

Screening RD

Tertiary prevention

Retinal Laser photocoagulation

Vitrectomy

Trattamento FOTOCOAGULAZIONE LASER

to seal
leaking blood vessels
(focal laser)




Figura 35. Trattamento diretto
Il trattamento diretto delle lesioni microvascolari al centro delle corone di essudati circostanti porta al riassorbimento degli essudati duri in poche settimane.



Figura 36. Trattamento diretto
La coagulazione delle lesioni che diffondono all'interno degli essudati circostanti porta alla loro scomparsa e al riassorbimento dell'edema.



Laser therapy to reduce
retinal oxygen demand
(scatter laser)




Figura 40. Trattamento diretto delle aree ischemiche
La fotocoagulazione delle aree di ischemia permette di osservare la regressione delle membrane neovascolari.








Figura 41. Trattamento diretto delle aree ischemiche
Dopo trattamento Laser delle aree ischemiche retiniche si nota in più del 90% dei casi una marcata regressione delle membrane neovascolari proliferanti.






Panfotocoagulazione laser (PFC)





La PFC deve essere eseguita:

- RD proliferante ad alto rischio con neovascolarizzazioni papillari o retiniche associate a emorragie preretiniche o vitreali
- RD proliferante non al alto rischio, RD non proliferante grave se il monitoraggio non è garantito

Trattamento




PFC





Controlli ogni 4 mesi
dopo il trattamento
Ritrattamento di lesioni
persistenti o recidivanti

Fotocoagulazione laser panretinica




Trattamento



Trattamento focale dell'Edema Maculare
(prima della PFC, se programmata)




Trattamento laser focale



Trattamento laser a griglia



Retinografia a colore



Fluorangiografia

Trattamento laser dell'edema maculare

EM clinicamente significativo non centrale

EM che coinvolge il centro della macula con riduzione della AV e spessore OCT $< 400 \mu\text{m}$

Terapia antiangiogenica


EM che coinvolge il centro della macula con riduzione della AV e spessore OCT $> 400 \mu\text{m}$

DIABETIC RETINOPATHY TREATMENT NEWER DEVELOPMENTS:

The use of anti-vascular endothelial growth factor antibodies has been shown to be useful in the treatment of DR

Anti-VEGF antibody treatment appears to be useful for both macular edema and proliferative retinopathy

Studies to determine the exact role of anti-VEGF treatment in relation to laser treatment in specific situations are underway.



Overview sul VEGF

Angiogenesi

FISIOLOGICA

- Embriogenesi
- Ciclo mestruale
- Riparazione ferite

PATOLOGICA

- Neoplasia
- Artrite
- Endometriosi
- Retinopatia diabetica
- DMLE essudativa
- Psoriasi
- Ulcere
- Ischemia
- Cardiovasculopatia




ECESSIVA

ANGIOGENESI

INSUFFICIENTE

Angiogenesi

Una serie ordinata di eventi altamente regolata



Fattori di Crescita Angiogenici


- Angiogenin
- Angiopoietin-1
 - Del-1
- Fibroblast growth factors: acidic (aFGF) and basic (bFGF)
 - Follistatin
 - Granulocyte colony-stimulating factor (G-CSF)
- Hepatocyte growth factor (HGF) /scatter factor (SF)
 - Interleukin-8 (IL-8)
 - Leptin
 - Midkine
 - Placental growth factor
- Platelet-derived endothelial cell growth factor (PD-ECGF)
 - Platelet-derived growth factor-BB (PDGF-BB)
 - Pleiotrophin (PTN)
 - Progranulin
 - Proliferin
 - Transforming growth factor-alpha (TGF-alpha)
 - Transforming growth factor-beta (TGF-beta)
 - Tumor necrosis factor-alpha (TNF-alpha)
- Vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF)

Fattori Inibenti l'Angiogenesi

- Angioarrestin
- Angiostatin (plasminogen fragment)
 - Antiangiogenic antithrombin III
 - Cartilage-derived inhibitor (CDI)
 - CD59 complement fragment
- Endostatin (collagen XVIII fragment)
 - Fibronectin fragment
 - Gro-beta
 - Heparinases
 - Heparin hexasaccharide fragment
- Human chorionic gonadotropin (hCG)
 - Interferon alpha/beta/gamma
 - Interferon inducible protein (IP-10)
 - Interleukin-12
- Kringle 5 (plasminogen fragment)
- Metalloproteinase inhibitors (TIMPs)
 - 2-Methoxyestradiol
- Placental ribonuclease inhibitor
- Plasminogen activator inhibitor
 - Platelet factor-4 (PF4)
 - Prolactin 16kD fragment
- Proliferin-related protein (PRP)
 - Retinoids
 - Tetrahydrocortisol-S
- Thrombospondin-1 (TSP-1)
- Transforming growth factor-beta (TGF-b)
 - Vasculostatin
- Vasostatin (calreticulin fragment)

Vascular Endothelial Growth Factor

- Glicoproteina omodimerica purificata e clonata nel 1989 da Ferrara¹
- Funzioni del VEGF
 - angiogenesi
 - permeabilita' vascolare
 - infiammazione
 - neuroprotezione



¹ Ferrara et al. *Biochem Biophys Res Commun.* 1989;161:851

Vascular Endothelial Growth Factor

- Gene del VEGF sul cromosoma 6

- Famiglia VEGF

VEGF-A

VEGF-B

VEGF-C

VEGF-D

VEGF-E

PlGF



- Isoforme VEGF-A

VEGF-A₁₂₁



VEGF-A₁₆₅

VEGF-A₁₈₉

VEGF-A₂₀₆



Recettori del VEGF



Recettori del VEGF

VEGFR-1^{1,2} Cruciale per l'embriogenesi
Non sembra fondamentale nella
angiogenesi patologica

VEGFR-2^{1,3} Il più importante nell'angiogenesi
tumorale
Media la maggior parte degli effetti
angiogenici del VEGF

VEGFR-3^{1,4} Presente solo nelle cellule endoteliali
linfatiche
Associato con metastasi linfonodali


¹Hicklin DJ, Ellis LM. *J Clin Oncol.* 2005;23:1011-1027

²Olofsson B, Korpelainen E, Pepper MS, et al. *Proc Natl Acad Sci USA.* 1998;95:11709-11714

³Ogawa S, Oku A, Sawano A, et al. *J Biol Chem.* 1998;273:31273-31282

⁴Dumont DJ, Jussila L, Taipale J, et al. *Science.* 1998;282:946-989




VEGF e occhio sano




- Elevata concentrazione VEGF nelle cellule dell'EPR
- I recettori per il VEGF sono prevalentemente localizzati sulle cellule endoteliali vascolari
- Ruolo nel mantenimento di un adeguato flusso ematico retinico

VEGF e patologia oculare

- DMLE neovascolare
- Retinopatia diabetica
- Occlusione venosa retinica
- ROP
- Neovascolarizzazione corneale ed iridea



VEGF e angiogenesi



- Attiva la degradazione della membrana basale delle cellule endoteliali
- Le cellule endoteliali:
 - ✓ modificano la loro forma ed invadono lo stroma
 - ✓ proliferano e migrano
 - ✓ aderiscono l'una all'altra e formano nuovi vasi




VEGF e permeabilità vasale



- 50.000 volte più potente dell'istamina
- Leakage vasale:
 - ✓ danno delle cell. endoteliali mediato dai leucociti
 - ✓ formazione fenestrature
 - ✓ alterazioni giunzioni strette

Ruolo del VEGF nella CNV

- **Fondamentale per l'angiogenesi**
- **Iperespressione VEGF nell'EPR induce CNV sperimentale**
- **Iperespressione VEGF nell'EPR dei pz affetti da AMD**
 - **Presenza VEGF in qualsiasi sottotipo di CNV, soprattutto le più vascolarizzate**



Spilsbury K et al. Overexpression of VEGF in RPE leads to the development of CNV. Am J Pathol, 2000

Kliffen M et al. Increased expression of angiogenic growth factors in ARM. Br J Ophthalmol, 1997

Kvanta A et al. Subfoveal fibrovascular membranes in ARM express VEGF. Invest Ophthalmol Vis Sci, 1996

Matsuoka M et al. Expression of pigment epithelium derived factor and VEGF in CNV and IPV. Br J Ophthalmol, 2004


**FARMACI ANTIANGIOGENICI IN
OFTALMOLOGIA
PER USO INTRAVITREALE**

Ranibizumab: Lucentis


Frammento (Fab) di un anticorpo monoclonale ricombinante anti VEGF-A (bevacizumab), umanizzato



rhu Mab
150 Kdaltons




rhu Fab
48 Kdaltons



rhu Fab V2

alta affinita' per tutte le isoforme biologicamente attive del VEGF-A (VEGF-A189, VEGF-A165, VEGF-A121, VEGF-A110)



Grazie per l'attenzione

